Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults with Treatment-Resistant Depression: A Case Series

0
30

    • Haigh EAP
    • Bogucki OE
    • Sigmon ST
    • et al.

    Depression Among Older Adults: A 20-Year Update on Five Common Myths and Misconceptions.

    The American Journal of Geriatric Psychiatry. 2018; 26 (): 107-122

    • Ford BC
    • Bullard KM
    • Taylor RJ
    • et al.

    Lifetime and 12-month prevalence of Diagnostic and Statistical Manual of Mental Disorders, disorders among older African Americans: findings from the National Survey of American Life.

    Am J Geriatr Psychiatry. 2007; 15: 652-659

    • Eaton WW
    • Kalaydjian A
    • Scharfstein DO
    • et al.

    Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981?2004.

    Acta Psychiatrica Scandinavica. 2007; 116 (): 182-188

    • Gum AM
    • King-Kallimanis B
    • Kohn R

    Prevalence of Mood, Anxiety, and Substance-Abuse Disorders for Older Americans in the National Comorbidity Survey-Replication The American.

    Journal of Geriatric Psychiatry. 2009; 17 (): 769-781

    • Trollor J
    • Brodaty H
    • Andrews G
    • et al.

    Prevalence of mental disorders in the elderly: the Australian National Mental Health and Well-being.

    Survey Acta Neuropsychiatrica. 2006; 18 (): 271-272

  • Depression in Long-Term Care.

    J Am Med Dir Assoc. 2008; 9: 82-87

    • Seitz D
    • Purandare N
    • Conn D

    Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review.

    Int Psychogeriatr. 2010; 22: 1025

  • Alexopoulos GS: Mechanisms and treatment of late-life depression Translational Psychiatry 2019; 9. Available at http://dx.doi.org/10.1038/s41398-019-0514-6.

  • Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms.

    Neurosci Biobehav Rev. 2017; 74: 277-286

    • Buigues C
    • Padilla-Sánchez C
    • Garrido JF
    • et al.

    The relationship between depression and frailty syndrome: a systematic review.

    Aging Ment Health. 2015; 19: 762-772

  • Depression in the elderly The.

    Lancet. 2005; 365 (): 1961-1970

    • Taylor WD
    • Aizenstein HJ
    • Alexopoulos GS

    The vascular depression hypothesis: mechanisms linking vascular disease with depression.

    Mol Psychiatry. 2013; 18: 963-974

    • Beekman ATF
    • Geerlings SW
    • Deeg DJH
    • et al.

    The natural history of late-life depression: a 6-year prospective study in the community.

    Arch Gen Psychiatry. 2002; 59: 605-611

    • Lyness JM
    • King DA
    • Cox C
    • et al.

    The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disability.

    J Am Geriatr Soc. 1999; 47: 647-652

    • Mitchell AJ
    • Subramaniam H

    Prognosis of depression in old age compared to middle age: a systematic review of comparative studies.

    Am J Psychiatry. 2005; 162: 1588-1601

    • Deng Y
    • McQuoid DR
    • Potter GG
    • et al.

    Predictors of recurrence in remitted late-life depression.

    Depress Anxiety. 2018; 35: 658-667

    • Conejero I
    • Olié E
    • Courtet P
    • et al.

    Suicide in older adults: current perspectives.

    Clin Interv Aging. 2018; 13: 691-699

    • Shah A
    • Bhat R
    • Zarate-Escudero S
    • et al.

    Suicide rates in five-year age-bands after the age of 60 years: the international landscape†.

    Aging & Mental Health. 2016; 20 (): 131-138

    • Deisenhammer EA
    • Ing C-M
    • Strauss R
    • et al.

    The Duration of the Suicidal Process.

    The Journal of Clinical Psychiatry. 2009; 70 (): 19-24

    • Schneider LS
    • Craig Nelson J
    • Clary CM
    • et al.

    An 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression American.

    Journal of Psychiatry. 2003; 160 (): 1277-1285

    • Sheikh JI
    • Cassidy EL
    • Doraiswamy PM
    • et al.

    Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness.

    J Am Geriatr Soc. 2004; 52: 86-92

    • Tollefson GD
    • Bosomworth JC
    • Heiligenstein JH
    • et al.

    A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression.

    Int Psychogeriatr. 1995; 7: 89-104

    • Rapaport MH
    • Schneider LS
    • Dunner DL
    • et al.

    Efficacy of controlled-release paroxetine in the treatment of late-life depression.

    J Clin Psychiatry. 2003; 64: 1065-1074

  • Depression in the Elderly.

    N Engl J Med. 2014; 371: 1228-1236

  • Escitalopram in the acute treatment of depressed patients aged 60 years or older.

    Am J Geriatr Psychiatry. 2008; 16: 14-20

    • Raskin J
    • Wiltse CG
    • Siegal A
    • et al.

    Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

    Am J Psychiatry. 2007; 164: 900-909

  • A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.

    Am J Geriatr Psychiatry. 2006; 14: 361-370

    • Oslin DW
    • Ten Have TR
    • Streim JE
    • et al.

    Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.

    J Clin Psychiatry. 2003; 64: 875-882

    • Kirby D
    • Harrigan S
    • Ames D

    Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit.

    Int J Geriatr Psychiatry. 2002; 17: 231-237

    • Laporte S
    • Chapelle C
    • Caillet P
    • et al.

    Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.

    Pharmacol Res. 2017; 118: 19-32

  • Methylphenidate augmentation of citalopram in elderly depressed patients.

    Am J Geriatr Psychiatry. 2001; 9: 298-303

    • Lenze EJ
    • Mulsant BH
    • Blumberger DM
    • et al.

    Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.

    Lancet. 2015; 386: 2404-2412

    • Rush AJ
    • John Rush A
    • Trivedi MH
    • et al.

    Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report.

    American Journal of Psychiatry. 2006; 163 (): 1905-1917

    • Machado-Vieira R
    • Baumann J
    • Wheeler-Castillo C
    • et al.

    The Timing of Antidepressant Effects: A Comparison of Diverse.

    Pharmacological and Somatic Treatments Pharmaceuticals. 2010; 3: 19-41

    • Murrough JW
    • Iosifescu DV
    • Chang LC
    • et al.

    Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

    Am J Psychiatry. 2013; 170: 1134-1142

    • Rosenblat JD
    • Carvalho AF
    • Li M
    • et al.

    Oral Ketamine for Depression: A Systematic Review.

    J Clin Psychiatry. 2019; 80

    • aan het Rot M
    • Collins KA
    • Murrough JW
    • et al.

    Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

    Biol Psychiatry. 2010; 67: 139-145

  • The use of ketamine as an antidepressant: a systematic review and meta-analysis Human Psychopharmacology.

    Clinical and Experimental. 2015; 30: 152-163

    • George D
    • Gálvez V
    • Martin D
    • et al.

    Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.

    Am J Geriatr Psychiatry. 2017; 25: 1199-1209

    • Ochs-Ross R
    • Daly EJ
    • Zhang Y
    • et al.

    Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3.

    Am J Geriatr Psychiatry. 2020; 28: 121-141

    • McIntyre RS
    • Rodrigues NB
    • Lee Y
    • et al.

    The Effectiveness of Repeated Intravenous Ketamine on Depressive Symptoms, Suicidal Ideation and Functional Disability in Adults with Major Depressive Disorder and Bipolar Disorder: Results from the Canadian Rapid Treatment Center of Excellence.

    J Affect Disord. 2020;

  • When at first you don’t succeed: sequential strategies for antidepressant nonresponders.

    J Clin Psychiatry. 1997; 58: 23-29

    • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders (DSM-5®).

    American Psychiatric Pub,
    2013 ()

    • Rodrigues NB
    • McIntyre RS
    • Lipsitz O
    • et al.

    Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence Expert Opin Drug Saf. June 2020; : 1-10

    • Rush AJ
    • Trivedi MH
    • Ibrahim HM
    • et al.

    The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

    Biol Psychiatry. 2003; 54: 573-583

    • Cusin C
    • Ionescu DF
    • Pavone KJ
    • et al.

    Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.

    Aust N Z J Psychiatry. 2017; 51: 55-64

    • Bremner JD
    • Douglas Bremner J
    • Krystal JH
    • et al.

    Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).

    Journal of Traumatic Stress. 1998; 11 (): 125-136

    • Singh JB
    • Fedgchin M
    • Daly E
    • et al.

    Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization.

    Placebo-Controlled Study Biol Psychiatry. 2016; 80: 424-431

    • Rong C
    • Park C
    • Rosenblat J
    • et al.

    Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.

    International Journal of Environmental Research and Public Health. 2018; 15 (): 771

    • Spitzer RL
    • Kroenke K
    • Williams JBW
    • et al.

    A brief measure for assessing generalized anxiety disorder: the GAD-7.

    Arch Intern Med. 2006; 166: 1092-1097

  • How to construct regression models for observational studies (and how NOT to do it!).

    Canadian Journal of Anesthesia/Journal canadien d’anesthésie. 2017; 64 (): 461-470

    • Hsu JH
    • Mulsant BH
    • Lenze EJ
    • et al.

    Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation.

    Am J Geriatr Psychiatry. 2016; 24: 918-922

    • Niciu MJ
    • Shovestul BJ
    • Jaso BA
    • et al.

    Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.

    J Affect Disord. 2018; 232: 310-315

    • van Schalkwyk GI
    • Wilkinson ST
    • Davidson L
    • et al.

    Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.

    J Affect Disord. 2018; 227: 11-16

    • Zanos P
    • Moaddel R
    • Morris PJ
    • et al.

    Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

    Pharmacological Reviews. 2018; 70 (): 621-660

    • Ochs-Ross R
    • Daly EJ
    • Zhang Y
    • et al.

    EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION.

    The American Journal of Geriatric Psychiatry. 2019; 27 (): S180-S181

    • McIntyre RS
    • Carvalho IP
    • Lui LMW
    • et al.

    The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.

    J Affect Disord. 2020; 276: 576-584

    • Irwin SA
    • Iglewicz A
    • Nelesen RA
    • et al.

    Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept.

    Trial J Palliat Med. 2013; 16: 958-965

    • McIntyre RS
    • Cha DS
    • Soczynska JK
    • et al.

    Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.

    Depress Anxiety. 2013; 30: 515-527

  • Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI).

    Curr Opin Psychiatry. 2016; 29: 48-55

  • Source link

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here